| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8781059 | Gynecologic Oncology Reports | 2018 | 4 Pages |
Abstract
- Neuroendocrine tumors (NETs) frequently occur in the lungs or the gastrointestinal tract; they are uncommon in the ovary.
- The mammalian target of rapamycin (mTOR) pathway has been reported as a treatment for advanced NETs.
- We describe a patient with an aggressive primary ovarian NET, successfully treated with everolimus (an mTOR inhibitor).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Michiko Kaiho-Sakuma, Masafumi Toyoshima, Mika Watanabe, Asami Toki, Satomi Kameda, Takamichi Minato, Hitoshi Niikura, Nobuo Yaegashi,